C4 Therapeutics appoints Utpal Koppikar to board; Elena Prokupets resigns

C4 Therapeutics, Inc.

Utpal Koppikar elected as director effective March 16, 2022; will chair Audit Committee and serve on Organization, Leadership and Compensation Committee.
Koppikar is CFO of Atara Biotherapeutics; previously VP at Gilead Sciences and executive director at Amgen.
Granted stock options for 41,200 shares vesting over three years with annual cliff.
Elena Prokupets resigned March 10, 2022; resignation not due to any disagreement with the company.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Elena Prokupets

Director

CCCC · C4 Therapeutics, Inc.

Effective: 2022-03-10
Filed: March 16, 2022, 7:59 PM ET

Elena Prokupets, Ph.D., resigned as a director and as a member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board.

Appointed

Utpal Koppikar

Director

CCCC · C4 Therapeutics, Inc.

Effective: 2022-03-16
Filed: March 16, 2022, 7:59 PM ET

elected Utpal Koppikar as a director effective immediately and as chair of the Audit Committee

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Elena Prokupets resigned as Director at C4 Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

Elena Prokupets, Ph.D., resigned as a director and as a member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Utpal Koppikar was elected as Director at C4 Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

elected Utpal Koppikar as a director effective immediately and as chair of the Audit Committee

View on SEC.gov

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-010644

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.